News

Aldeyra had received 2 complete response letters (CRL) from the FDA in April 2025 and November 2023 for past submissions.

Deep learning discerns IIH, NAION, and normal eyes using single fundus image.

The phase 2/3 clinical trial for OCU410ST will enroll 51 participants diagnosed with Stargardt disease.

A study reveals significant retinal vessel changes in diabetic retinopathy, highlighting the need for early detection methods to prevent vision loss.

The LYNX LIO is the latest generation of pattern scanning lasers that were first introduced in 2006.

NASA’s development of autonomous eye imaging technologies for astronauts aboard the International Space Station is paving the way for remote, high-quality eye care both in deep space and underserved regions on Earth.

Advanced autofluorescence reveals cellular pigment reservoirs with therapeutic potential at the Heidelberg 2025 International SPECTRALIS Symposium – And Beyond (ISS).

Funding will support the continued clinical advancement of its lead ocular implant candidate, PA5108, for the reduction of IOP in patients with ocular hypertension and glaucoma.

The rationale for the study under discussion is that the experience level of the operating surgeon is a potential factor affecting the outcomes of all ophthalmic procedures, including ISBCS

Findings presented at the Heidelberg 2025 International SPECTRALIS Symposium — And Beyond (ISS) suggest detailed structural data could better inform therapeutic targeting and monitoring.

Improved axial resolution allows clearer visualization of early atrophic changes, including iRORA vs cRORA differentiation, as shared at the Heidelberg 2025 International SPECTRALIS Symposium – And Beyond (ISS).

From basal laminar deposits to foveal centering, a new framework refines what clinicians see—and what they treat—in outer retinal disease, as presented at the Heidelberg 2025 International SPECTRALIS Symposium – And Beyond (ISS).

EssilorLuxottica and MidEuropa recently entered into an agreement that will allow EssilorLuxottica to acquire Optegra, building upon its med-tech strategy.

Amneal Pharmaceuticals received FDA approval for its prednisolone acetate ophthalmic suspension, a steroid eye inflammation treatment referencing Allergan’s Pred Forte, with a US launch planned for Q3 2025.

Lamivudine could provide an oral option to more effectively treat DME at a lower cost to patients

Harrow expects BYQLOVI to be commercially available in the fourth quarter of 2025.

The novel preservative-free eye drop therapy for glaucoma aims to improve IOP control and patient adherence with a fixed-dose combination.

Compared with penicillin, investigators reported no significant differences in the incidence of ophthalmologic manifestations among patients treated with ceftriaxone.

Cabozantinib is a vascular endothelial growth factor receptor tyrosine kinase inhibitor, a drug used as a therapy for several malignancies.

FDA noted that the US phase 2 trial may serve as 1 of the 2 pivotal trials required for NDA filing.

With 35+ lectures, a NASA keynote, and a river cruise through historic Heidelberg, this year’s symposium blends science and scenery

Siegfried Priglinger, MD discussed research he presented focused on pediatric patients with inherited retinal diseases with an emphasis on studies into the RPE65 gene.

The gift will be used to treat and potentially cure eye diseases such as macular degeneration and glaucoma, increase focus on basic science, and harness artificial intelligence to revolutionize vision care.

TGFBI corneal dystrophy is a group of genetic eye disorders caused by mutations in the TGFBI gene, resulting in abnormal protein buildup in the stromal layer of the cornea.